Growth hormone and treatment outcomes: Expert review of current clinical practice

Fernando Cassorla, Stefano Cianfarani, Fritz Haverkamp, Jose I. Labarta, Sandro Loche, Xiaoping Luo, Mohamad Maghnie, Veronica Mericq, Agota Muzsnai, Svante Norgren, Marja Ojaniemi, Zuzana Pribilincova, Sofia Quinteiro, Lars Savendahl, Angela Spinola E Castro, Christoph Gasteyger

Research output: Contribution to journalArticlepeer-review


Although there are guidelines for treatment of short stature, open questions regarding optimal management of growth hormone therapy still exist. Experts attending six international meetings agree that successful therapy results in the patient attaining mid-parental height, and relies on correct diagnosis and early intervention. Experts advocate patient follow-up every 3-6 months, and that growth and adherence should be monitored at each visit. Growth response is variable, and an accepted definition of good/poor response is lacking. Combined with patient education and regular patient follow-up, a definition of treatment response could lead to improved treatment outcomes. Few experts use prediction models in clinical practice, but all agree that pharmacogenetics might improve prediction, enable early therapy modulation, and promote growth. Poor growth is often due to low adherence. Guidance on optimal management of growth hormone therapy is required, with focus on early diagnosis, dosing, treatment monitoring, adherence, and motivation.

Original languageEnglish
Pages (from-to)554-565
Number of pages12
JournalPediatric Endocrinology Reviews
Issue number2
Publication statusPublished - Dec 2011


  • Adherence
  • Growth hormone deficiency
  • Growth response
  • Short stature

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Growth hormone and treatment outcomes: Expert review of current clinical practice'. Together they form a unique fingerprint.

Cite this